Fibroblast Gross Factor-23 and Arterial Stiffness in Hemodialysis Patient

Abstract

FGF23 is a free circulating hormone secreted by osteocytes affecting mainly phosphate metabolism as it inhibits its renal tubular reabsorption by suppressing the expression of luminal sodium-phosphate co –transporters (Na Pi). FGF23 serum levels rise progressively as renal function declines early in chronic kidney disease stages 2-3. FGF23 should not be taken only as a biomarker of serum phosphate, but also a predictor of progression of chronic kidney disease, development of secondary hyperparathyroidism and mortality among cardiovascular disease patients. The present study enrolled 30 living end stage renal disease patients on regular hemodialysis randomly slected from hemodialysis unit at Ain Shams university hospitals after exclusion of patients of known cardiovascular disease or ischemic heart disease,also patients of age below 18 years and above 50 years were excluded as well as patients having arterio venous fistulas on both arms.